BioMarin Pharmaceutical’s treatment of hypochondroplasia was granted orphan designation by the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- BioMarin price target lowered to $108 from $118 at Stifel
- BioMarin raises FY23 non-GAAP EPS view to $1.85-$2.10 from $1.80-$2.05
- BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
- BioMarin reports Q2 non-GAAP EPS 54c, consensus 23c
- BioMarin options imply 2.3% move in share price post-earnings